Scientists are developing a new class of medicines called macrocyclic peptides, which may help target diseases that have been difficult to treat with traditional drugs.
The research is focused on making large peptide molecules that can behave like both:
- Small pills (easy to take orally)
- Antibody drugs (highly precise targeting)
What the research is about
The article explains how researchers are trying to solve a long-standing problem in drug development:
Some disease targets inside the body are considered “undruggable”, meaning:
- They are too complex for small-molecule drugs
- They are too difficult for traditional antibodies to reach effectively
Macrocyclic peptides are being designed to fill this gap.
What macrocyclic peptides are
Macrocyclic peptides are:
- Large, ring-shaped molecules
- Made from amino acids (like proteins)
- Typically between 500–2,000 Daltons in size
They are inspired by natural compounds such as cyclosporin A, a fungus-derived drug already used as an oral immunosuppressant.
Even though they are large, some can still be taken as pills.
Why scientists are interested
Researchers say these molecules could combine the best features of existing drug types:
- From antibodies: strong and precise targeting of disease proteins
- From small molecules: easier delivery, including potential oral use
- From natural biology: ability to interact with complex protein surfaces
This makes them useful for:
- Cancer
- Autoimmune diseases
- Cardiometabolic conditions
- Rare diseases
Why this matters for drug development
Traditionally, scientists followed a rule that:
- Oral drugs should be under 500 Daltons
But macrocyclic peptides break this rule, yet still show activity in the body.
Examples like cyclosporin A (over 1,200 Daltons) prove that large molecules can still work as oral drugs in certain cases.
What makes them difficult to develop
Despite their promise, macrocyclic peptides are hard to design and produce because:
- They are chemically complex
- Their structure must be precisely controlled
- They need to be stable enough to survive in the body
- They must reach the right target inside cells
How scientists are solving this
Researchers are using new tools such as:
- Machine learning models to design molecules
- Automated chemical synthesis systems
- High-throughput screening methods to test thousands of compounds
One example is biotech companies like Unnatural Products, which combine AI and robotics to design and test peptide drugs faster.
The big opportunity
Scientists believe macrocyclic peptides could:
- Target disease proteins that current drugs cannot reach
- Offer oral alternatives to injectable antibody drugs
- Expand treatment options for complex diseases
However, experts also note that this is still an emerging field, and many challenges remain before these drugs become widely available.
Key takeaway
Macrocyclic peptides are being developed as a “middle ground” between pills and biologic drugs, with the potential to unlock treatments for diseases that have long been considered out of reach.